Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prostate cancer: Ablation yields poor survival vs radiotherapy

Key clinical finding: Radiotherapy is associated with superior survival outcomes in patients with low- and intermediate-risk localized prostate cancer vs. focal laser ablation (FLA).

Major finding: FLA was associated with significantly worse overall survival vs. radiotherapy (adjusted hazard ratio, 1.49; P less than .001).

Study details: The data come from an analysis of patients with low- and intermediate-risk prostate cancer from the Surveillance, Epidemiology, and End Results program who received radiotherapy (n = 93,041) or laser ablation (n = 428).

Disclosures: The study was supported by The National Key Research and Development Program of China, West China Hospital, Sichuan University, the National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, and the Prostate Cancer Foundation Young Investigator Award 2013. The authors declared no conflicts of interest.


Zhou X et al. Sci Rep. 2020 Jun 4. doi: 10.1038/s41598-020-65863-8.